编号：2022-07 投资者关系 特定对象调研 分析师会议 活动类别 □媒体采访 □业绩说明会 □新闻发布会 路演活动 现场参观 其他 电话会议 证券代码： 688089 证券简称： 嘉必优 嘉必优生物技术（武汉）股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------|-----------------------------------| | | | | | 参与单位名称及 | 机构名称 | 参会人员 | | 人员姓名 | 5 | 月 11 日 15:00-15:50 | | | UBS | Mandy Liu | | | New Silk Road Investment | Xin Feng | | | Manulife AM | Wenlin Li | | | Sage Partner | Joey Zou | | | WT capital | Ray Fang | | | Ironbirch | Davey C. Leu | | | 5 | 月 13 日 14:00-15:30 | | | 泰 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥102,096,355.32, representing a year-on-year increase of 17.62%[5] - The net profit attributable to shareholders for the same period was ¥27,841,760.00, showing a decline of 16.60% compared to the previous year[5] - Total operating revenue for the first three quarters of 2022 reached ¥273,244,476.30, an increase of 9.3% compared to ¥249,908,128.65 in the same period of 2021[22] - Net profit for the first three quarters of 2022 was ¥75,304,227.69, a decrease of 27.8% from ¥104,179,165.99 in the same period of 2021[23] - Basic earnings per share for the third quarter of 2022 were ¥0.65, down from ¥0.84 in the same quarter of 2021[24] - The total profit for the first three quarters of 2022 was ¥86,642,442.11, down 10.7% from ¥97,107,838.54 in the same period of 2021[32] Research and Development - The R&D expenses for Q3 2022 totaled ¥11,663,668.37, which is an increase of 99.55% year-on-year, reflecting the company's commitment to expanding its R&D efforts[11] - The proportion of R&D expenses to operating revenue increased to 11.42%, up by 4.69 percentage points from the previous year[6] - Research and development expenses for the first three quarters of 2022 were ¥26,333,080.29, compared to ¥17,352,441.12 in the same period of 2021, reflecting a significant investment in innovation[22] - Research and development expenses increased to ¥23,355,921.81, up 53.0% from ¥15,279,592.55 in the previous year[32] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥83,502,609.85, marking an increase of 56.45% compared to the same period last year[6] - The net cash flow from operating activities for the first three quarters of 2022 was CNY 83,502,609.85, an increase of 56.4% compared to CNY 53,374,936.52 in the same period of 2021[25] - The company's cash and cash equivalents decreased to CNY 386,592,981.73 from CNY 664,467,646.87, representing a decline of about 42%[17] - The company's cash and cash equivalents at the end of the period were CNY 382,905,701.10, slightly up from CNY 364,748,739.86 at the end of the previous year[26] - The cash flow from financing activities resulted in a net outflow of -CNY 6,704,513.99, an improvement from -CNY 39,600,000.00 in the same period last year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,541,758,615.76, representing a growth of 6.44% from the end of the previous year[6] - The equity attributable to shareholders at the end of the reporting period was ¥1,428,729,447.17, an increase of 3.45% compared to the previous year[6] - Total liabilities as of the end of the third quarter of 2022 amounted to ¥111,224,600.46, compared to ¥66,677,032.94 at the end of the same period in 2021[20] - The total liabilities increased to CNY 165,419,076.55 from CNY 119,249,041.44, representing a rise of 38.7%[30] - The company's total equity as of September 30, 2022, was CNY 1,425,025,639.81, an increase from CNY 1,379,574,266.50 at the end of 2021, showing a growth of 3.3%[30] Shareholder Information - The company reported a total of 5,570 common shareholders at the end of the reporting period[13] - The company reported a total of 53,100,000 shares held by Wuhan Xiwang Biological Engineering Co., accounting for 44.25% of total shares[14] Investment Activities - Total cash inflow from investment activities was CNY 593,707,456.91, up from CNY 297,485,123.75 in the previous year, indicating a significant increase of 99.7%[26] - The net cash flow from investment activities was -CNY 357,604,092.53, an improvement from -CNY 493,450,082.63 in the same period last year[26] - The company reported a net cash outflow from investing activities of ¥363,550,227.99, an improvement from a net outflow of ¥497,072,258.59 in the previous year[36] Operational Costs - Total operating costs for the first three quarters of 2022 were ¥210,886,748.75, up 31.1% from ¥160,807,974.69 in the previous year[22] - The company reported a total of CNY 147,348,154.50 in cash paid for goods and services, which is an increase of 44.8% compared to CNY 101,668,089.28 in the previous year[25]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 171,148,120.98, representing a 4.93% increase compared to CNY 163,108,902.46 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 25.96% to CNY 50,023,996.90 from CNY 67,566,742.60 year-on-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 35,892,316.09, down 23.41% from CNY 46,860,881.53 in the previous year[19]. - Basic earnings per share decreased by 25.00% to CNY 0.42 compared to the same period last year[20]. - Diluted earnings per share also decreased by 25.00% to CNY 0.42 compared to the same period last year[20]. - The total profit for the first half of 2022 was CNY 56,764,023.80, a decrease of 30.6% compared to CNY 81,710,377.91 in the first half of 2021[174]. - The company's net profit for the first half of 2022 was CNY 41,155,064.12, compared to CNY 60,656,131.82 in the same period of 2021, reflecting a decrease of 32.1%[173]. Cash Flow and Investments - The net cash flow from operating activities increased significantly by 122.69% to CNY 90,455,918.15, compared to CNY 40,618,997.36 in the same period last year[19]. - The company's cash and cash equivalents decreased by 31.34% to CNY 456,242,956.66, primarily due to unexpired bank financial products[75]. - The total cash inflow from sales of goods and services was ¥200,937,480.28, an increase from ¥142,596,615.14 in the first half of 2021, representing a growth of about 40.7%[180]. - The cash inflow from investment activities totaled ¥295,435,444.60, down from ¥424,202,066.91 in the previous year, reflecting a decrease of about 30.3%[185]. - The net cash flow from investment activities was -¥354,873,504.91, compared to -¥260,665,496.35 in the same period of 2021, indicating a worsening of 36.0%[185]. Research and Development - R&D investment as a percentage of operating revenue increased by 1.51 percentage points to 8.57%[20]. - The total R&D investment for the first half of 2022 was approximately ¥14.67 million, representing a 27.48% increase from ¥11.51 million in the same period last year[42]. - The company has obtained 9 new patents in the first half of 2022, bringing the total number of patents to 86[41]. - The company has developed high-value products such as 2'-FL, 3'-SL, astaxanthin, and EPA, with 2'-FL achieving 96% purity and currently in regulatory approval phase[36]. - The company is establishing an intelligent R&D platform to integrate synthetic biology research, smart fermentation testing, and high-throughput detection, reducing the time from strain construction to industrialization[35]. Market and Sales Strategy - International sales accounted for nearly 50% of total revenue in the first half of 2022, with ongoing negotiations with multiple international clients[58]. - The company has formed long-term partnerships with major clients such as Nestlé and Danone, enhancing its brand reputation and customer resource base[56]. - The company is actively expanding its international supply chain and distribution channels, covering over 30 countries and regions[56]. - The domestic sales model primarily relies on direct sales, while the international market uses a distributor-based approach, facilitating rapid market expansion[29]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[119]. Environmental Compliance - The company has implemented a comprehensive waste gas treatment system, including five water washing towers and a UV purification system, to ensure compliance with emission standards[96]. - The company has established emergency response plans for environmental incidents at both the GeDian and Jiangxia branches, conducting regular drills and filing with local environmental authorities[100]. - The company has not faced any administrative penalties for environmental issues during the reporting period[106]. - The company has committed to sustainability initiatives, aiming to reduce carbon emissions by 50% by 2025[129]. - The company replaced refrigerants in cooling facilities with a new fluorine-free refrigerant, achieving a 10% increase in cooling capacity and an average energy efficiency improvement of over 20%[107]. Shareholder and Financial Management - The company plans to maintain a dividend payout ratio of 30% to ensure shareholder returns while reinvesting in growth initiatives[119]. - The company has committed to a stable cash dividend policy to ensure consistent returns for investors, with plans to improve the profit distribution system[117]. - The company will comply with relevant laws and regulations regarding share reduction, including trading methods such as centralized bidding and block trading[114]. - The company has pledged to take corrective actions if it fails to meet its commitments regarding immediate return dilution, including public apologies and alternative commitments[117]. - The company has extended the lock-up period for its restricted shares by six months following the expiration date[134].

Financial Performance - The company's operating revenue for Q1 2022 was ¥75,542,426.37, representing a decrease of 4.17% compared to the same period last year[5] - The net profit attributable to shareholders was ¥23,224,988.14, down 31.20% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥14,031,578.96, a decline of 38.84% compared to the previous year[5] - Basic earnings per share were ¥0.19, reflecting a decrease of 32.14% year-on-year[6] - Net profit for Q1 2022 was ¥22,013,486.90, down 36.8% from ¥34,920,460.94 in Q1 2021[20] - Operating profit decreased to ¥19,512,167.40, a decline of 43.0% compared to ¥34,263,660.01 in Q1 2021[19] - The net profit for Q1 2022 was CNY 26,050,579.71, down from CNY 36,339,817.81 in Q1 2021, indicating a decline of 28.5%[27] - The overall comprehensive income for Q1 2022 was ¥22,707,014.78, consistent with the net profit reported[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,470,211,469.37, an increase of 1.50% from the end of the previous year[6] - The total number of common shareholders at the end of the reporting period was 5,670[10] - The company's cash and cash equivalents decreased to RMB 537,873,200.84 from RMB 664,467,646.87, representing a decline of about 19.0%[14] - The total current assets were reported at RMB 914,550,554.92, down from RMB 994,851,368.32, indicating a decrease of approximately 8.1%[14] - The company's long-term equity investments increased to RMB 40,264,899.30 from RMB 19,916,010.74, showing a significant growth of about 102.0%[14] - The total non-current assets rose to RMB 555,660,914.45 from RMB 453,639,525.42, marking an increase of approximately 22.5%[15] - The total liabilities decreased to RMB 55,897,974.91 from RMB 59,954,131.55, reflecting a reduction of about 6.8%[15] - Total liabilities decreased to ¥62,510,769.55 from ¥66,677,032.94 year-over-year[19] Cash Flow - The net cash flow from operating activities was ¥64,335,059.13, with significant improvement in receivables collection[9] - Cash flow from operating activities was ¥64,335,059.13, a significant improvement from a negative cash flow of -¥9,239,874.45 in Q1 2021[21] - Operating cash flow for Q1 2022 was ¥68,211,951.27, a significant improvement from a net cash outflow of ¥6,919,018.15 in Q1 2021[30] - Total cash inflow from operating activities was ¥143,336,265.90, compared to ¥67,946,369.30 in the same period last year, representing an increase of 110.5%[29] - The company reported a net cash outflow from investing activities of ¥189,490,113.90 in Q1 2022, an improvement from a larger outflow of ¥556,503,779.29 in Q1 2021[30] - The net cash flow from investment activities was -CNY 187,471,146.88, compared to -CNY 556,515,753.28 in the previous period[22] Research and Development - Research and development expenses totaled ¥6,121,712.21, accounting for 8.10% of operating revenue, an increase of 0.93 percentage points[6] - Research and development expenses for Q1 2022 were ¥6,121,712.21, slightly down from ¥5,657,883.23 in Q1 2021[19] - Research and development expenses for Q1 2022 were CNY 5,491,702.14, compared to CNY 4,924,930.92 in Q1 2021, reflecting an increase of 11.5%[27] Shareholder Equity - Total equity attributable to shareholders increased to ¥1,406,162,330.85 from ¥1,381,023,990.59 in the previous year[19] - The total equity increased to CNY 1,404,674,681.28 from CNY 1,379,574,266.50, showing a growth of 1.8%[27] Inventory and Other Assets - The company's accounts receivable decreased to RMB 122,112,077.98 from RMB 151,078,051.73, a decline of approximately 19.2%[14] - The inventory increased slightly to RMB 75,259,339.09 from RMB 74,855,595.02, indicating a marginal growth of about 0.5%[14] - The company reported a significant increase in other non-current assets to RMB 106,723,838.63 from RMB 74,891,804.01, representing a growth of approximately 42.5%[15] - The company's inventory as of March 31, 2022, was CNY 72,588,888.45, slightly up from CNY 72,413,944.54 at the end of 2021[24] Financial Management - The company's short-term borrowings and other financial liabilities were not disclosed in the report, indicating a focus on maintaining liquidity and managing debt levels[15] - The company did not report any cash inflow from financing activities in Q1 2022, indicating a focus on internal funding[30] - The company has not applied new accounting standards for the current year, maintaining consistency in financial reporting[31]

Financial Performance - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2021 was CNY 351,109,348.43, representing an increase of 8.55% compared to 2020[20]. - The net profit attributable to shareholders of the listed company decreased by 1.54% to CNY 128,578,881.86 in 2021[20]. - The net cash flow from operating activities decreased by 29.20% to CNY 103,291,182.60 compared to the previous year[20]. - The basic earnings per share for 2021 was CNY 1.07, a decrease of 1.83% from 2020[21]. - The total assets at the end of 2021 were CNY 1,448,490,893.74, reflecting a 4.75% increase from the end of 2020[20]. - The company's net assets attributable to shareholders increased by 4.79% to CNY 1,381,023,990.59 at the end of 2021[20]. - The company reported a significant increase in revenue, achieving a total of 8,207 million RMB, with a net profit of 3,094.72 million RMB, indicating a significant increase compared to the previous period[91]. - The company reported a total revenue of 4,471,643 million, reflecting a significant growth of 873.80% compared to the previous year[172]. Research and Development - Research and development expenses accounted for 8.81% of operating revenue, an increase of 2.51 percentage points from 2020[21]. - The company’s R&D investment exceeded CNY 30 million in 2021, focusing on synthetic biology technology and collaborations with research institutions[36]. - Total R&D investment reached ¥30,947,095.88, a significant increase of 51.82% compared to ¥20,384,052.34 in the previous year, with R&D investment accounting for 8.81% of operating revenue[85]. - The company reported a significant increase in R&D activities, with a focus on innovative food ingredients and health-related products[81]. - The company has filed for numerous patents, enhancing its core technology capabilities and reducing product costs[78]. - The company aims to integrate existing technologies to continuously innovate in product development and application solutions[76]. Market Expansion and Strategy - The company plans to continue focusing on R&D and market expansion strategies to enhance future performance[22]. - The company is expanding its production capacity with ongoing projects in microencapsulation and microbial oil refining, enhancing operational efficiency[36]. - The company is focusing on international market expansion, particularly in Australia and Southeast Asia, to capture a larger share of the global ARA and DHA markets[155]. - The company aims to achieve over 100 million in sales for its Omega-3 fatty acid product line in 2022, leveraging diverse strains and enhancing process technology to reduce costs[157]. - The company is exploring market expansion strategies, aiming to penetrate new geographical regions and increase market share[172]. Product Development - The company established a new business unit for animal nutrition and launched 8 new feed or feed additive products during the reporting period[34]. - New product developments include OPO and fucoidan lactose, which have completed pilot studies and are moving towards industrialization[77]. - The company is expanding its market presence through the development of new products, including a refined microbial oil and a new type of polyunsaturated fatty acid oil[81]. - The company is focusing on expanding its product offerings in the baking sector with new formulations that include DHA microcapsules[81]. - The company introduced a new subscription model, which is anticipated to increase recurring revenue by 20% over the next year[184]. Governance and Compliance - The company has received a standard unqualified audit report from Da Xin Accounting Firm[5]. - The company’s financial report is guaranteed to be true, accurate, and complete by its management team[6]. - The company has no significant differences in governance compared to regulations set by the China Securities Regulatory Commission[164]. - The company’s governance structure remains compliant with relevant laws and regulations, ensuring no major conflicts of interest with controlling shareholders[165]. - The company held a total of 8 board meetings during the year, with 3 conducted via communication methods[192]. Industry Trends and Risks - The biotechnology industry is recognized as a strategic emerging industry in China, with government support for biotechnological advancements and sustainable practices[45]. - The nutrition and health industry is rapidly growing in China, driven by increasing consumer health awareness and an aging population, positioning China as a major player in the global nutrition market[46]. - The company faces risks related to food safety and product quality control, which are critical in the infant formula sector[106]. - The company is exposed to raw material price volatility, which could negatively impact production costs and profitability[108]. - The company is navigating risks from intensified market competition and potential adverse changes in downstream industries[109]. Customer and Supplier Relationships - The company’s top five customers accounted for 72.38% of total sales, with no sales to related parties[127]. - The top five suppliers contributed to 43.78% of total purchases, with no purchases from related parties[128]. - Total procurement amount from top 5 suppliers reached 2,053.45 million RMB, accounting for 43.78% of annual procurement[130]. - The company has formed long-term stable partnerships with renowned infant formula companies such as Nestlé and Danone, with some collaborations lasting over 10 years[103]. Sustainability and Innovation - The company is committed to sustainability by developing methods for producing food-grade sialic acid and other health-oriented ingredients[81]. - The company aims to improve resource and energy utilization efficiency while promoting sustainable industry development[88]. - The company is focusing on sustainability initiatives, aiming to reduce carbon emissions by 30% by 2025[182]. - The company is enhancing its smart manufacturing capabilities to achieve a green production model, incorporating automation and digitalization into its production processes[155].

Financial Performance - The company's operating revenue for Q3 2021 was ¥86,799,226.19, representing a year-over-year increase of 1.76%[5] - The net profit attributable to shareholders decreased by 14.18% to ¥33,381,698.78 for the same period[5] - The net profit after deducting non-recurring gains and losses was ¥21,801,554.04, down 14.51% year-over-year[5] - Net profit for the third quarter of 2021 was ¥104,179,165.99, down from ¥113,843,435.64 in the same quarter of 2020, reflecting a decrease of approximately 8.8%[23] - Earnings per share for the third quarter of 2021 were ¥0.84, compared to ¥0.92 in the same quarter of 2020, showing a decline of about 8.7%[24] - The company reported a total comprehensive income of ¥104,007,803.01 for the third quarter of 2021, down from ¥113,595,784.77 in the same quarter of 2020, indicating a decrease of approximately 8.5%[24] Research and Development - Research and development expenses totaled ¥5,844,964.91, an increase of 55.01% compared to the previous year[6] - R&D expenses accounted for 6.73% of operating revenue, up 2.31 percentage points from the previous year[6] - The company plans to continue increasing investment in new business R&D and expanding its R&D team size[10] - Research and development expenses for the third quarter of 2021 were ¥17,352,441.12, up from ¥11,773,569.80 in the same period of 2020, representing an increase of about 47.8%[22] Cash Flow and Liquidity - Cash flow from operating activities showed a significant decline of 53.73% to ¥53,374,936.52 year-to-date[6] - Operating cash inflow for the first three quarters of 2021 was CNY 267,521,499.22, a decrease of 16.1% compared to CNY 318,864,151.12 in the same period of 2020[26] - The company reported a net cash flow from operating activities of CNY 53,374,936.52, significantly lower than CNY 115,354,810.57 in Q3 2020, indicating a decline of 53.7%[27] - Cash and cash equivalents were reported at ¥367,239,854.04, down from ¥847,316,269.30 in December 2020, indicating a significant reduction of about 56.6%[16] - Cash received from investment recovery was CNY 285,587,000.00, down 39.6% from CNY 473,000,000.00 in the previous year[27] - Total cash inflow from investment activities was CNY 297,485,123.75, a decrease of 38.4% compared to CNY 482,478,424.66 in the same period of 2020[27] - The net increase in cash and cash equivalents for Q3 2021 was CNY -480,089,700.86, slightly better than CNY -515,688,143.26 in Q3 2020[28] Assets and Liabilities - Total assets increased by 1.92% to ¥1,409,391,243.45 compared to the end of the previous year[6] - The total assets as of the end of the third quarter of 2021 amounted to ¥1,409,391,243.45, slightly up from ¥1,382,820,690.79 at the end of the previous year[18] - Total liabilities for the third quarter of 2021 were ¥54,877,055.97, a decrease from ¥59,301,062.31 in the same period of 2020, representing a reduction of approximately 7.2%[18] - The company's total non-current assets reached ¥386,810,615.08, an increase from ¥259,680,565.72 in the previous year, indicating a growth of approximately 48.9%[18] Shareholder Information - The company reported a total of 53,100,000 restricted shares held by domestic state-owned legal entities, with no shares under lock-up conditions[13] - The top ten shareholders include Beiyou Limited with 14,490,000 shares and China Merchants Bank with 4,503,851 shares, indicating significant institutional ownership[14] - The company has not disclosed any related party transactions or agreements among shareholders, ensuring transparency in ownership structure[14] Operating Costs - Total operating costs for the first three quarters of 2021 were ¥160,807,974.69, compared to ¥139,782,813.28 in 2020, indicating an increase of about 15.1%[22] - The company’s total operating expenses increased to CNY 214,146,562.70, compared to CNY 203,509,340.55 in the same period last year, reflecting a rise of 5.3%[27]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[19]. - The company's operating revenue for the first half of the year was ¥163,108,902.46, an increase of 8.05% compared to the same period last year[20]. - The net profit attributable to shareholders decreased by 5.12% to ¥67,566,742.60 compared to the same period last year[20]. - The net cash flow from operating activities dropped significantly by 53.96% to ¥40,618,997.36 compared to the same period last year[20]. - Basic earnings per share decreased by 5.08% to ¥0.56 compared to the same period last year[21]. - The company reported a significant increase in revenue, achieving a total of $500 million for the first half of 2021, representing a 25% year-over-year growth[128]. - The company reported a net profit margin of 12%, up from 10% in the previous quarter, reflecting improved operational efficiency[134]. - The total revenue for the period reached 1,249,575,165, with a slight increase compared to the previous period[199]. Research and Development - The company is investing RMB 30 million in R&D for new technologies aimed at enhancing product efficacy and safety[19]. - The company's R&D expenditure as a percentage of operating revenue increased by 1.76 percentage points to 7.06% compared to the same period last year[21]. - The company increased its R&D investment by 43.79% year-on-year, totaling ¥11,507,476.21, compared to ¥8,002,955.65 in the previous period[46]. - The company is investing in new technology development, allocating $50 million towards R&D initiatives aimed at enhancing product features and user experience[128]. - The company has initiated technical development for new products such as human milk oligosaccharides and has expanded its product applications into the cosmetics sector[40]. - The company has filed for 11 new patents in the first half of 2021, all of which are invention patents[41]. Market Expansion - Future outlook includes a projected revenue growth of 25% for the second half of 2021, driven by new product launches and market expansion strategies[19]. - Market expansion efforts are focused on Southeast Asia, with plans to enter three new countries by the end of 2021[19]. - The company is actively developing new applications for SA in personal care and cosmetics, indicating a strategic expansion into new markets[29]. - Market expansion plans include entering three new international markets by the end of 2021, which is projected to increase overall market share by 5%[128]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $200 million earmarked for potential targets[128]. Sustainability and Compliance - The management highlighted a commitment to sustainability, with initiatives aimed at reducing carbon emissions by 10% in the next year[19]. - The company remains committed to sustainability initiatives, with plans to reduce carbon emissions by 30% over the next five years[128]. - The company has implemented a robust food safety and supply chain management system, achieving certifications such as ISO9001 and FSSC22000[61]. - The company has established a commitment to transparency and accountability, accepting supervision from regulatory bodies and the public[124]. - The company will ensure that all fundraising activities comply with relevant laws and regulations to avoid fraudulent practices[120]. Shareholder and Investor Relations - The company will implement a stable cash dividend policy to ensure continuous and stable returns to investors[120]. - The company has committed to actively manage and supervise the use of raised funds to mitigate risks and improve efficiency[120]. - The company will strengthen its investor return system and maintain a focus on reasonable investment returns[120]. - The company has outlined a three-year plan for shareholder dividend returns following its public offering[124]. - The company guarantees to compensate for any losses incurred by shareholders due to violations of the commitment letter, effective from the date of signing until the company is no longer a shareholder[136]. Operational Efficiency - The company has maintained a strong cash position, with cash and cash equivalents totaling RMB 50 million as of the end of the reporting period[19]. - Operating costs rose by 9.28% to ¥71,853,483.07, primarily due to the increase in revenue[75]. - The company aims to reduce operational costs by 15% through efficiency improvements in the supply chain[116]. - The company has implemented cost-cutting measures that are expected to save approximately $20 million annually, enhancing overall profitability[128]. Environmental Management - The company reported a wastewater discharge of 51,076 tons from the Gedian branch and 59,530 tons from the Jiangxia branch in the first half of 2021, both meeting the discharge standards[100]. - The company has established a wastewater treatment facility at the Gedian branch with a design capacity of 800 tons per day, and the Jiangxia branch's facility has a capacity of 400 cubic meters per day[100]. - The company has implemented a two-stage spraying + UV light decomposition deodorization system for exhaust treatment in the fermentation workshop[101]. - The company has joined the Alashan SEE Ecological Association in May 2021, actively participating in environmental protection initiatives[111]. Corporate Governance - The company has not reported any significant changes in its board or management personnel during the reporting period[90]. - The company has not faced any penalties or violations related to its directors, supervisors, or senior management during the reporting period[144]. - The company has ensured that all related party transactions are conducted at market prices to maintain fairness[145].

Financial Performance - Operating revenue for the first quarter was ¥78,829,125.16, representing a growth of 41.47% year-on-year[5]. - Net profit attributable to shareholders of the listed company was ¥33,755,464.12, up by 33.12% compared to the same period last year[5]. - The net profit after deducting non-recurring gains and losses was ¥22,943,817.63, an increase of 25.82% year-on-year[5]. - Basic and diluted earnings per share were both ¥0.28, reflecting a growth of 33.33% compared to the previous year[5]. - The company reported a basic earnings per share of RMB 0.28, up 33.95% from RMB 0.21 in the same quarter last year[14]. - Net profit for Q1 2021 was ¥34,920,460.94, representing a 33.5% increase compared to ¥26,165,983.19 in Q1 2020[26]. - The company's net profit for Q1 2021 was CNY 30,888,845.13, an increase of 24.6% compared to CNY 24,869,740.10 in Q1 2020[30]. Revenue and Costs - The operating costs increased by 49.25% to RMB 36,909,551.39 from RMB 24,729,599.22, primarily due to the growth in operating revenue[14]. - Total operating costs for Q1 2021 were ¥50,963,252.55, up 56.9% from ¥32,499,184.56 in Q1 2020[25]. - Total revenue from sales of goods and services in Q1 2021 was CNY 69,446,652.09, an increase of 13.8% from CNY 60,973,599.77 in Q1 2020[31]. Research and Development - Research and development expenses accounted for 7.18% of operating revenue, an increase of 0.51 percentage points from the previous year[5]. - Research and development expenses rose by 52.25% to RMB 5,657,883.23, reflecting increased investment in new product development[14]. - Research and development expenses for Q1 2021 totaled ¥5,657,883.23, an increase of 52.4% from ¥3,716,081.05 in Q1 2020[25]. Cash Flow and Assets - The net cash flow from operating activities was -¥9,239,874.45, a decrease of 115.63% compared to the same period last year[5]. - The cash flow from operating activities showed a significant decline, with a net outflow of RMB -9,239,874.45 compared to a net inflow of RMB 59,120,168.55 in the previous year[14]. - The total monetary funds decreased by 66.65% to RMB 282,584,262.85 from RMB 847,316,269.30, mainly due to the purchase of bank wealth management products[13]. - The cash and cash equivalents at the end of Q1 2021 were CNY 279,404,885.04, down from CNY 374,213,008.21 at the end of Q1 2020[32]. - The company experienced a net cash outflow of CNY -565,433,555.68 in Q1 2021, compared to CNY -470,106,287.03 in Q1 2020[32]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,396,974,472.58, an increase of 1.02% compared to the end of the previous year[5]. - Current assets totaled RMB 1,131,760,224.96, slightly up from RMB 1,123,140,125.07, indicating a growth of about 0.2%[18]. - Total liabilities decreased to RMB 49,520,649.01 from RMB 59,301,062.31, a reduction of about 16.5%[19]. - Shareholders' equity increased to RMB 1,347,453,823.57 from RMB 1,323,519,628.48, reflecting a growth of approximately 1.8%[20]. - Non-current assets totaled RMB 265,214,247.62, up from RMB 259,680,565.72, indicating an increase of about 2.0%[18]. Shareholder Information - The total number of shareholders at the end of the reporting period was 5,200[10]. - The largest shareholder, Wuhan Xinyuan Bioengineering Co., Ltd., held 44.25% of the shares[11].

Financial Performance - The company's operating revenue for 2020 was CNY 323,460,668.81, representing a 3.82% increase compared to CNY 311,547,812.06 in 2019[20]. - The net profit attributable to shareholders for 2020 was CNY 130,585,376.79, which is a 10.50% increase from CNY 118,173,427.66 in 2019[20]. - The net cash flow from operating activities for 2020 was CNY 145,882,192.43, up by 10.56% from CNY 131,947,334.97 in 2019[20]. - The company's total assets at the end of 2020 were CNY 1,382,820,690.79, reflecting a 6.55% increase from CNY 1,297,831,523.59 at the end of 2019[20]. - The basic earnings per share for 2020 decreased to CNY 1.09, down 16.79% from CNY 1.31 in 2019[21]. - The company's main business revenue for the reporting period was CNY 323,255,196.35, with a gross profit margin of 55.02%, reflecting a year-on-year increase of 3.83%[130]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion, representing a 25% year-over-year growth[171]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 6.30% in 2020, up from 6.01% in 2019[21]. - The company achieved a total R&D investment of ¥20,384,052.34, representing an 8.86% increase compared to the previous year[64]. - The company filed 33 new invention patents during the year, bringing the total number of patents to 176, with 60 patents granted[62]. - The company is focusing on the development of microbial oil production technology, which is expected to enhance resource efficiency and reduce waste emissions[69]. - The company is actively developing new products, including algal DHA and natural β-carotene, to enhance its competitive edge in the market[87]. - The company plans to strengthen its research and development efforts by collaborating with leading universities and research institutions to advance its technology platform[150]. Market and Product Development - The company’s main business includes the R&D, production, and sales of polyunsaturated fatty acids and natural β-carotene, widely used in infant formula and dietary supplements[29]. - The global dietary supplement market exceeds $100 billion, with North America and Europe accounting for approximately 70% of consumption[40]. - The company is exploring the application of sialic acid in treating metabolic disorders related to Alzheimer's disease, showcasing its research in neuroprotective solutions[59]. - The company aims to enhance its core technology innovation by focusing on high-throughput screening, intelligent fermentation control, and product purification, which will improve production efficiency and reduce costs[146]. - The company plans to expand its product application areas, targeting human nutrition, animal nutrition, cosmetics, and pharmaceuticals, to create a comprehensive application system[147]. Corporate Governance and Compliance - The company emphasizes the importance of accurate financial reporting and governance practices[4]. - The company has received a standard unqualified audit report from Da Xin Certified Public Accountants[4]. - The company has a clear and compliant decision-making process for profit distribution, ensuring transparency and accountability in the distribution of dividends[154]. - The company has maintained a robust compliance framework for its dividend policy, ensuring that all procedures are followed diligently[154]. - The company has committed to ensuring that related party transactions with Jia Biyou are conducted fairly and in accordance with market standards to protect the interests of shareholders, especially minority shareholders[182]. Risk Factors - The report highlights various risk factors including core competitiveness risk, operational risk, industry risk, and macroeconomic risk[4]. - The company faced risks related to raw material and energy price fluctuations, which could adversely affect production costs and profitability[90]. - The company is exposed to potential risks from the agreement with DSM, including the possibility of reduced net profit if DSM fails to comply with the contract[89]. Shareholder Relations and Dividends - The company plans to distribute a cash dividend of 3.30 CNY per 10 shares, totaling approximately 39.6 million CNY, which represents 30.32% of the net profit attributable to shareholders for 2020[5]. - The company has not proposed any cash profit distribution plan for the reporting period despite having positive distributable profits[156]. - The company has committed to a stable and continuous cash dividend policy to ensure reasonable returns for investors[163]. - The company will enhance its investor relations management to ensure timely, accurate, and complete information disclosure, thereby maintaining investor trust[150]. Strategic Partnerships and Collaborations - The company has formed long-term partnerships with major clients such as Cargill and Feihe, enhancing its brand reputation and customer base[81]. - The company collaborates with well-known enterprises in the infant formula sector, distributing products to over 30 countries and regions[45]. - The company invested a total of $3.06 million in the second phase of its investment in Pharmaco, holding a 14.46% stake, to develop a global supply chain[84]. Future Outlook - The company anticipates a significant increase in consumer demand for preventive health foods, with 45% of European consumers increasing nutritional elements in their diets due to the pandemic[145]. - The company plans to continue investing in R&D to maintain its competitive edge in the nutrition and health food industry[54]. - The company is actively involved in national and provincial technology projects, enhancing its competitive edge in the industry[76].

Financial Performance - Operating income for the first nine months rose by 2.19% to CNY 236,256,283.53 compared to the same period last year[6] - Net profit attributable to shareholders increased by 14.69% to CNY 110,107,131.47 for the first nine months[6] - The total net profit for the third quarter was CNY 73,382,893.58, reflecting a 10.71% increase year-on-year[6] - Total operating revenue for Q3 2020 was CNY 85,296,622.21, a slight increase of 1.47% compared to CNY 84,061,610.73 in Q3 2019[26] - Net profit for Q3 2020 reached CNY 40,296,130.64, representing a 20.00% increase from CNY 33,307,091.17 in Q3 2019[28] - Total profit for the first three quarters of 2020 was approximately ¥122.24 million, compared to ¥111.40 million in the same period of 2019, reflecting a growth of 9.92%[32] Cash Flow - Net cash flow from operating activities surged by 57.78% to CNY 115,354,810.57 year-to-date[6] - The company's operating cash flow increased by 57.78% to ¥115,354,810.57, driven by increased sales collections[16] - Cash flow from operating activities for the first three quarters of 2020 was approximately ¥115.35 million, a significant increase from ¥73.11 million in the same period of 2019[35] - The company reported a net cash outflow from investing activities of approximately ¥569.14 million for the first three quarters of 2020[35] - Cash and cash equivalents at the end of the period were RMB 318,358,715.02, down from RMB 837,921,073.56 at the beginning of the year[37] Assets and Liabilities - Total assets increased by 3.84% to CNY 1,347,692,587.72 compared to the end of the previous year[6] - Current assets totaled CNY 1,098,716,982.84, slightly down from CNY 1,099,062,852.60 in the previous year, indicating a decrease of about 0.03%[19] - Total liabilities decreased to CNY 44,521,637.86 from CNY 48,256,358.50, a reduction of approximately 7.3%[20] - Total liabilities as of Q3 2020 amounted to CNY 53,976,286.15, an increase from CNY 46,764,345.24 in the previous year[24] - The company reported a total equity of RMB 1,249,575,165.09, consistent with the previous period[41] Shareholder Information - Total number of shareholders reached 5,360[13] - Wuhan Xiwang Bioengineering holds 53,100,000 shares, representing 44.25% of total shares[13] - The number of shares held by the top ten unrestricted shareholders includes 1,285,289 shares held by the National Social Security Fund[14] Research and Development - R&D expenditure as a percentage of operating income decreased by 0.96 percentage points to 4.98%[8] - Research and development expenses for Q3 2020 were CNY 3,770,614.15, a decrease of 36.14% from CNY 5,906,335.71 in Q3 2019[27] - The company plans to continue expanding its investment in new projects and technologies[16] Investment Activities - Long-term equity investments increased by 422.41% to ¥67,724,731.98, primarily due to investments in Pharmamark Nutrition Pty Ltd and Suzhou Dingshi Huize Biotechnology Investment Fund[15] - Investment income rose significantly to ¥11,509,054.80, an increase of 8,748.77% compared to the previous year[15] - The company reported a decrease in prepayments by RMB 999,885.13, reflecting changes in contract liabilities[44] Financial Expenses - The company’s financial expenses decreased significantly due to increased interest income[15] - The company incurred a financial expense of approximately ¥604.46 thousand in Q3 2020, compared to a financial income of approximately ¥733.11 thousand in Q3 2019[32]